International Journal of Radiation Oncology * Biology * Physics
Volume 64, Issue 1 , Pages 26-32 , 1 January 2006

Advances in understanding angiogenesis through molecular studies

  • Mijung Kwon, Ph.D.
    • ,
  • Steven K. Libutti, M.D.

      Affiliations

    • Corresponding Author InformationReprint request to: Steven K. Libutti, M.D., Surgery Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Room 4W-5940, Bethesda, MD 20892-1201. Tel: (301) 496-5049; Fax: (301) 402-1788

Received 15 November 2004 ,Revised 10 March 2005 ,Accepted 11 March 2005.

References 

  1. Folkman J , Klagsburn M . Angiogenic factors . Science . 1987;235:442–447
  2. Folkman J . What is the evidence that tumors are angiogenesis dependent? . J Natl Cancer Inst . 1990;82:4–6
  3. Carmeliet P . Angiogenesis in health and disease . Nat Med . 2003;9:653–660
  4. Hanahan D , Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis . Cell . 1996;86:353–364
  5. Hahnfeldt P , Panigrahy D , Folkman J , et al.   Tumor development under angiogenic signaling (A dynamical theory of tumor growth, treatment response, and postvascular dormancy) . Cancer Res . 1999;59:4770–4775
  6. Benjamin LE , Keshet E . Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors (Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal) . Proc Natl Acad Sci U S A . 1997;94:8761–8766
  7. Holmgren L , O’Reilly MS , Folkman J . Dormancy of micrometastases (Balanced proliferation and apoptosis in the presence of angiogenesis suppression) . Nat Med . 1995;1:149–153
  8. Gimbrone MAJ , Leapman SB , Cotran RS , et al.   Tumor dormancy in vivo by prevention of neovascularization . J Exp Med . 1972;136:261–276
  9. Folkman J . Fundamental concepts of the angiogenic process . Curr Mol Med . 2003;3:643–651
  10. Watnick RS , Cheng YN , Rangarajan A , et al.   Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis . Cancer Cell . 2003;3:219–231
  11. Folkman J , Hahnfeldt P , Hlatky L . The logic of anti-angiogenic gene therapy . In:  Friedmann T editors. The development of human gene therapy . New York: Cold Spring Harbor Laboratory Press; 1999;p. 527–543
  12. Wary KK . Molecular targets for anti-angiogenic therapy . Curr Opin Mol Ther . 2004;6:54–70
  13. Ziche M , Donnini S , Morbidelli L . Development of new drugs in angiogenesis . Curr Drug Targets . 2004;5:485–493
  14. O’Reilly MS , Holmgren L , Shing Y , et al.   Angiostatin (A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma) . Cell . 1994;79:315–328
  15. O’Reilly MS , Boehm T , Shing Y , et al.   Endostatin (An endogenous inhibitor of angiogenesis and tumor growth) . Cell . 1997;88:277–285
  16. Gutheil JC , Campbell TN , Pierce PR , et al.   Targeted antiangiogenic therapy for cancer using Vitaxin (A humanized monoclonal antibody to the integrin alphavbeta3) . Clin Cancer Res . 2000;6:3056–3061
  17. Margolin K , Gordon MS , Holmgren E , et al.   Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer (Pharmacologic and long-term safety data) . J Clin Oncol . 2001;19:851–856
  18. Costouros NG , Libutti SK . Microarray technology and gene expression analysis for the study of angiogenesis . Expert Opin Biol Ther . 2002;2:545–556
  19. Zogakis TG , Costouros NG , Kruger EA , et al.   Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay . Biotechniques . 2002;33:664–666 668, 670
  20. Ferreras M , Felbor U , Lenhard T , et al.   Generation and degradation of human endostatin proteins by various proteinases . FEBS Lett . 2000;486:247–251
  21. Dixelius J , Cross MJ , Matsumoto T , et al.   Endostatin action and intracellular signaling (Beta-catenin as a potential target?) . Cancer Lett . 2003;196:1–12
  22. Thomas JP , Arzoomanian RZ , Alberti D , et al.   Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors . J Clin Oncol . 2003;21:223–231
  23. Abdollahi A , Hahnfeldt P , Maercker C , et al.   Endostatin’s antiangiogenic signaling network . Mol Cell . 2004;13:649–663
  24. Jimenez B , Volpert OV , Crawford SE , et al.   Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 . Nat Med . 2000;6:41–48
  25. Ruzinova MB , Schoer RA , Gerald W , et al.   Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors . Cancer Cell . 2003;4:277–289
  26. Mazzanti CM , Tandle A , Lorang D , et al.   Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells . Genome Res . 2004;14:1585–1593
  27. Ingber D , Fujita T , Kishimoto S , et al.   Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth . Nature . 1990;348:555–557
  28. Yet SF , McA’Nulty MM , Folta SC , et al.   Human EZF, a Kruppel-like zinc finger protein, is expressed in vascular endothelial cells and contains transcriptional activation and repression domains . J Biol Chem . 1998;273:1026–1031
  29. Lyden D , Young AZ , Zagzag D , et al.   Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts . Nature . 1999;401:670–677
  30. Mok SC , Wong KK , Chan RK , et al.   Molecular cloning of differentially expressed genes in human epithelial ovarian cancer . Gynecol Oncol . 1994;52:247–252
  31. Chua EL , Young L , Wu WM , et al.   Cloning of TC-1 (C8orf4), a novel gene found to be overexpressed in thyroid cancer . Genomics . 2000;69:342–347
  32. Zhang W , Chuang YJ , Swanson R , et al.   Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells . Blood . 2004;103:1185–1191
  33. Iozzo RV , San Antonio JD . Heparan sulfate proteoglycans (Heavy hitters in the angiogenesis arena) . J Clin Invest . 2001;108:349–355
  34. Salvucci O , Basik M , Yao L , et al.   Evidence for the involvement of SDF-1 and CXCR4 in the disruption of endothelial cell-branching morphogenesis and angiogenesis by TNF-alpha and IFN-gamma . J Leukoc Biol . 2004;76:217–226
  35. Salvucci O , Yao L , Villalba S , et al.   Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1 . Blood . 2002;99:2703–2711
  36. Cline EI , Bicciato S , DiBello C , et al.   Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling . Cancer Res . 2002;62:7143–7148
  37. Westphal JR . Technology evaluation (ABT-510, Abbott) . Curr Opin Mol Ther . 2004;6:451–457
  38. Reiher FK , Volpert OV , Jimenez B , et al.   Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics . Int J Cancer . 2002;98:682–689
  39. Kanno S , Oda N , Abe M , et al.   Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells . Oncogene . 2000;19:2138–2146
  40. Watanabe K , Hasegawa Y , Yamashita H , et al.   Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis . J Clin Invest . 2004;114:898–907
  41. Minami T , Horiuchi K , Miura M , et al.   Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis . J Biol Chem . 2004;279:50537–50554
  42. Klee CB , Ren H , Wang X . Regulation of the calmodulin-stimulated protein phosphatase, calcineurin . J Biol Chem . 1998;273:13367–13370
  43. Bussolati B , Deambrosis I , Russo S , et al.   Altered angiogenesis and survival in human tumor-derived endothelial cells . FASEB J . 2003;17:1159–1161
  44. Liotta LA , Kohn EC . The microenvironment of the tumour-host interface . Nature . 2001;411:375–379
  45. Barcellos-Hoff MH , Brooks AL . Extracellular signaling through the microenvironment (A hypothesis relating carcinogenesis, bystander effects, and genomic instability) . Radiat Res . 2001;156:618–627
  46. Feldman AL , Stetler-Stevenson WG , Costouros NG , et al.   Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism . Cancer Res . 2004;64:4481–4486
  47. Stetler-Stevenson WG , Krutzsch HC , Liotta LA . TIMP-2 (Identification and characterization of a new member of the metalloproteinase inhibitor family) . Matrix Suppl . 1992;1:299–306
  48. Seo DW , Li H , Guedez L , et al.   TIMP-2 mediated inhibition of angiogenesis (An MMP-independent mechanism) . Cell . 2003;114:171–180
  49. Keyse SM . Protein phosphatases and the regulation of mitogen-activated protein kinase signalling . Curr Opin Cell Biol . 2000;12:186–192
  50. Keyse SM . Protein phosphatases and the regulation of MAP kinase activity . Semin Cell Dev Biol . 1998;9:143–152
  51. Berra E , Pages G , Pouyssegur J . MAP kinases and hypoxia in the control of VEGF expression . Cancer Metastasis Rev . 2000;19:139–145
  52. Pages G , Milanini J , Richard DE , et al.   Signaling angiogenesis via p42/p44 MAP kinase cascade . Ann N Y Acad Sci . 2000;902:187–200
  53. Rousseau S , Houle F , Landry J , et al.   p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells . Oncogene . 1997;15:2169–2177
  54. Tanaka K , Abe M , Sato Y . Roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis . Jpn J Cancer Res . 1999;90:647–654
  55. Kiemer AK , Weber NC , Furst R , et al.   Inhibition of p38 MAPK activation via induction of MKP-1 (Atrial natriuretic peptide reduces TNF-alpha-induced actin polymerization and endothelial permeability) . Circ Res . 2002;90:874–881
  56. Englert CR , Baibakov GV , Emmert-Buck MR . Layered expression scanning (Rapid molecular profiling of tumor samples) . Cancer Res . 2000;60:1526–1530
  57. Charles CH , Sun H , Lau LF , et al.   The growth factor-inducible immediate-early gene 3CH134 encodes a protein-tyrosine-phosphatase . Proc Natl Acad Sci U S A . 1993;90:5292–5296
  58. Lin WW , Hsu YW . Cycloheximide-induced cPLA(2) activation is via the MKP-1 down-regulation and ERK activation . Cell Signal . 2000;12:457–461
  59. Carmeliet P , Jain RK . Angiogenesis in cancer and other diseases . Nature . 2000;407:249–257
  60. Ruzinova MB , Benezra R . Id proteins in development, cell cycle and cancer . Trends Cell Biol . 2003;13:410–418
  61. Di Cristofano A , Kotsi P , Peng YF , et al.   Impaired Fas response and autoimmunity in Pten+/− mice . Science . 1999;285:2122–2125
  62. Di Cristofano A , De Acetis M , Koff A , et al.   Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse . Nat Genet . 2001;27:222–224
  63. Folkman J , Kalluri R . Cancer without disease . Nature . 2004;427:787
  64. Zorick TS , Mustacchi Z , Bando SY , et al.   High serum endostatin levels in Down syndrome (Implications for improved treatment and prevention of solid tumours) . Eur J Hum Genet . 2001;9:811–814
  65. Iughetti P , Suzuki O , Godoi PH , et al.   A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma . Cancer Res . 2001;61:7375–7378

PII: S0360-3016(05)00442-6

doi: 10.1016/j.ijrobp.2005.03.024

International Journal of Radiation Oncology * Biology * Physics
Volume 64, Issue 1 , Pages 26-32 , 1 January 2006

Article Tools

* Image Usage & Resolution